title: [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review].
abstract: OBJECTIVE
  To assess and compare the effectiveness and safety of methylphenidate immediate-release tablets (IR-MPH), methylphenidate controlled release tablets (OROS-MPH) and atomoxetine (AHC) for attention deficit hyperactivity disorder (ADHD) in Chinese children.
  
  
  METHODS
  Randomized or clinical controlled trials on the effectiveness and safety of IR-MPH, OROS-MPH and AHC for ADHD were searched in electronic databases of CNKI, VIP, CBMDISC online, PubMed, Embase and MEDLINE. Two reviewers independently extracted the data and assessed the quality of the included literatures.
  
  
  RESULTS
  Eight trials were finally included. IR-MPH, OROS-MPH and AHC were effective for ADHD. OROS-MPH was superior to IR-MPH in the improvement of peer relationship, CGI-I score, mother satisfaction and psychosomatic problems. There were no significant differences in the effectiveness between the AHC and IR-MPH groups. The adverse events related to the therapy with IR-MPH, OROS-MPH or AHC were mild and the incidence rates of adverse events were not significantly different among the three groups.
  
  
  CONCLUSIONS
  The effectiveness of OROS-MPH for the treatment of ADHD is probably superior to IR-MPH, and the effectiveness between AHC and IR-MPH is similar. The three drugs demonstrate the safety and well tolerance.
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
authors.forename: Xiao-Zhen
authors.initials: XZ
authors.lastname: Lv
authors.forename: Zheng
authors.initials: Z
authors.lastname: Shu
authors.forename: Yao-Wen
authors.initials: YW
authors.lastname: Zhang
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Wu
authors.forename: Si-Yan
authors.initials: SY
authors.lastname: Zhan
mesh_terms: D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D011437:Propylamines; D013607:Tablets; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride